Janssen Vaccines & Prevention B.V.
- Address
- Archimedesweg 4-6
Sponsor Overview
Specializations
Infectious Disease Prevention
Janssen Vaccines & Prevention B.V. focuses on the prevention of invasive extraintestinal pathogenic Escherichia coli disease in older adults, with particular attention to infections arising from ExPEC O-serotypes linked to bloodstream and sterile-site infection.
- Invasive ExPEC disease
- Escherichia coli infection prevention
- Older adult infectious disease risk
The company’s research activity is concentrated in adult populations with prior urinary tract infection history and other groups at elevated risk for severe bacterial disease.
Vaccine Development
The sponsor’s work centers on vaccine-based prevention against ExPEC-related disease, reflecting a therapeutic interest in reducing invasive bacterial outcomes through targeted immunisation.
- ExPEC9V vaccine
- Bacterial vaccine immunisation
- Serotype-specific protection
Its clinical portfolio also addresses protection against multiple ExPEC serotypes associated with invasive disease in adult and older populations.
Seasonal Influenza Vaccination
Janssen Vaccines & Prevention B.V. also studies the interaction between an ExPEC vaccine and a high-dose quadrivalent seasonal influenza vaccine, with interest in maintaining immune responses to influenza strains during co-administration.
- Influenza vaccination
- Quadrivalent seasonal influenza vaccine
- Co-administration with bacterial vaccines
This area links bacterial and respiratory immunisation strategies in adults aged 65 years and older.
Immunogenicity and Safety in Older Adults
The sponsor’s trials place emphasis on humoral immune response, safety, and reactogenicity in ageing populations, especially where vaccination is intended to protect against both bacterial and influenza-related disease.
- Humoral immunity
- Vaccine safety
- Reactogenicity
Its clinical research is directed toward adults 60 years and older, including those with increased susceptibility to invasive infection.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Immunogenicity, Safety, and Reactogenicity of JNJ-78901563 and High-Dose Quadrivalent Influenza Vaccine in Adults Aged 65 Years or Older |  Belgium Poland | Not Recruiting |
| Phase 3 Evaluation of ExPEC9V Vaccine for Preventing Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60+ with Prior Urinary Tract Infection |  Czechia Denmark France Germany Spain Sweden The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 14 molecules, of which 9 are not being studied by other sponsors.
This sponsor has worked with 59 sites across their trial portfolio.
Therapeutic Focus
- 1.Bacterial Infections and Mycoses2 trials180 other sponsors
Partnered Research Centres
59 centres- Address
- Moelleparkvej 4, 9000 Aalborg
- Address
- Delnicka 120, 252 41 Dolni Brezany
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- Nistelrodeseweg 10, 5406 PT Uden
- Address
- Valhallavagen 1, Karlskrona Stadsfoers, 371 41 Karlskrona
- Address
- 2 Avenue Martin Luther King, 87000 Limoges
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Janssen Vaccines & Prevention B.V..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.